Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sight Sciences, Inc.

Get SEC filing alerts via email and in your feed for Sight Sciences, Inc.

SGHT

Sight Sciences, Inc.

About Sight Sciences, Inc.

Sight Sciences, Inc. develops interventional ophthalmic technologies targeting prevalent eye diseases like glaucoma and dry eye. Its core products include MIGS devices (OMNI, SION) for glaucoma and TearCare for dry eye, used by eye care professionals worldwide. The company's solutions focus on restoring natural eye function through evidence-based, minimally invasive procedures, emphasizing clinical efficacy, patient comfort, and market access to improve patient outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Sight Sciences, Inc.

1
1
Sight Sciences, Inc. Sight Sciences Reports 12.5% Revenue Growth to $19.7 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Sight Sciences, Inc. Sight Sciences Reports 3.1% Revenue Decline to $77.4 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Sight Sciences, Inc. Sight Sciences Reports Q3 2025 Revenue of $19.9 Million, Net Loss of $8.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Sight Sciences, Inc. Sight Sciences Reports Q2 2025 Revenue Decline of 8.5% to $19.6 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Sight Sciences, Inc. Sight Sciences Reports 9.1% Revenue Decline to $17.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Sight Sciences, Inc. Sight Sciences Reports $79.9 Million Revenue for Fiscal Year 2024, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Sight Sciences, Inc. Sight Sciences Reports Mixed Q3 Results, Net Loss Improves by 15.1%

Via official filing (AI summary) | over 1 year ago | 0 comments